Pain reduction in either the knee or the hip with subcutaneous tanezumab: a pooled analysis in patients with moderate to severe osteoarthritis and a history of inadequate response to other analgesics

Abstract

Purpose: Tanezumab, a monoclonal antibody against nerve growth factor, demonstrated efficacy in 2 recently completed placebo-controlled clinical trials that enrolled patients with moderate-to-severe symptomatic osteoarthritis (OA) of the knee or hip and a history of inadequate response to standard OA analgesics. We performed a post-hoc analysis to assess tanezumab efficacy in patients with an index joint of the knee and, separately, an index joint of the hip.